Mike Dombeck leads Corporate Development for Precision BioSciences, where he has responsbility for Business Development, Alliance Management, Portfolio Management, and Public Relations. He led the excution of Precision's key partnerships with Baxalta for CAR T therapies, Gilead for gene editing therapies to treat Hepatitis B, and the University of Pennsylvania to investigate in vivo gene editing therapeutics.
Prior to joining Precision, Mike was a Director in GlaxoSmithKline’s R&D Strategy and Portfolio Management group. Mike has nearly 20 years of industry experience, spanning market research and portfolio planning with Talecris, business development for DarPharma, Inc., business development and corporate strategy consulting with Campbell Alliance, and as a co-founder of Cempra Pharmaceuticals.
2:30 PM–3:45 PM Jun 5, 2018 (US - Eastern)